Recognition of conserved antigens by Th17 cells provides broad protection against pulmonary Haemophilus influenzae infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 30, 2018, Pages E7149-E7157

  Li, Wenchao ^a,b   Zhang, Xinyun ^b,c   Yang, Ying ^b   Yin, Qingqin ^b,d   Wang, Yan ^b   Li, Yong ^a,b   Wang, Chuan ^b   Wong, Sandy M ^e   Wang, Ying ^a   Goldfine, Howard ^b   Akerley, Brian J ^e   Shen, Hao ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c FUDAN UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Antigenic diversity; Haemophilus influenzae; Pneumonia; Th17 responses; Vaccine

Indexed keywords

CURDLAN; INFLUENZA VACCINE; BACTERIAL ANTIGEN; HAEMOPHILUS VACCINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; CROSS PROTECTION; CYTOSOLIC FRACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; IMMUNITY; IMMUNIZATION; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MOUSE; NONHUMAN; NONTYPEABLE HAEMOPHILUS INFLUENZAE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; TH17 CELL; ANIMAL; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROSS REACTION; IMMUNOLOGY; KNOCKOUT MOUSE; MICROBIOLOGY; PATHOLOGY;

ANIMALS; ANTIGENS, BACTERIAL; CROSS REACTIONS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; MICE; MICE, KNOCKOUT; PNEUMONIA, BACTERIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TH17 CELLS;

EID: 85052021871     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1802261115     Document Type: Article

References (53)

1. Price EP, et al. (2015) Haemophilus influenzae: Using comparative genomics to accurately identify a highly recombinogenic human pathogen. BMC Genomics 16: 641.
2. De Chiara M, et al. (2014) Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure. Proc Natl Acad Sci USA 111:5439–5444.
3. Puig C, et al. (2014) Clinical and molecular epidemiology of haemophilus influenzae causing invasive disease in adult patients. PLoS One 9:e112711.
4. Agrawal A, Murphy TF (2011) Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. J Clin Microbiol 49:3728–3732.
5. Leibovitz E, Jacobs MR, Dagan R (2004) Haemophilus influenzae: A significant pathogen in acute otitis media. Pediatr Infect Dis J 23:1142–1152.
6. Van Eldere J, Slack MP, Ladhani S, Cripps AW (2014) Nontypeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis 14:1281–1292.
7. Sethi S, Evans N, Grant BJ, Murphy TF (2002) New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347:465–471.
8. Sethi S, et al. (2016) Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection 44:65–76.
9. Zaura E, et al. (2015) Same exposure but two radically different responses to antibiotics: Resilience of the salivary microbiome versus long-term microbial shifts in feces. MBio 6:e01693-15.
10. Poolman JT, et al. (2000) Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 19(Suppl 1):S108–S115.
11. Murphy TF (2015) Vaccines for nontypeable Haemophilus influenzae: The future is now. Clin Vaccine Immunol 22:459–466.
12. Kyd JM, Cripps AW (1998) Potential of a novel protein, OMP26, from nontypeable Haemophilus influenzae to enhance pulmonary clearance in a rat model. Infect Immun 66:2272–2278.
13. Kyd JM, Dunkley ML, Cripps AW (1995) Enhanced respiratory clearance of nontypeable Haemophilus influenzae following mucosal immunization with P6 in a rat model. Infect Immun 63:2931–2940.
14. Jalalvand F, Littorin N, Su YC, Riesbeck K (2014) Impact of immunization with Protein F on pulmonary clearance of nontypeable Haemophilus influenzae. Vaccine 32: 2261–2264.
15. Prymula R, et al. (2006) Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet 367:740–748.
16. Vesikari T, et al. (2016) Effectiveness of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugated vaccine (PHiD-CV) against carriage and acute otitis media-a double-blind randomized clinical trial in Finland. J Pediatric Infect Dis Soc 5:237–248.
17. Siggins MK, et al. (2015) PHiD-CV induces anti-Protein D antibodies but does not augment pulmonary clearance of nontypeable Haemophilus influenzae in mice. Vaccine 33:4954–4961.
18. Gilsdorf JR (1998) Antigenic diversity and gene polymorphisms in Haemophilus influenzae. Infect Immun 66:5053–5059.
19. Clementi CF, Murphy TF (2011) Non-typeable Haemophilus influenzae invasion and persistence in the human respiratory tract. Front Cell Infect Microbiol 1:1.
20. Swords WE (2012) Nontypeable Haemophilus influenzae biofilms: Role in chronic airway infections. Front Cell Infect Microbiol 2:97.
21. Bandi V, et al. (2001) Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 164:2114–2119.
22. Sharma SK, Casey JR, Pichichero ME (2011) Reduced memory CD4+ T-cell generation in the circulation of young children may contribute to the otitis-prone condition. J Infect Dis 204:645–653.
23. Abe Y, et al. (2002) Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165:967–971.
24. Ye P, et al. (2001) Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 194:519–527.
25. Freches D, et al. (2013) Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology 140:220–231.
26. Kimizuka Y, et al. (2012) Roles of interleukin-17 in an experimental Legionella pneumophila pneumonia model. Infect Immun 80:1121–1127.
27. Milner JD, et al. (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:773–776.
28. Gawronski JD, Wong SM, Giannoukos G, Ward DV, Akerley BJ (2009) Tracking insertion mutants within libraries by deep sequencing and a genome-wide screen for Haemophilus genes required in the lung. Proc Natl Acad Sci USA 106:16422–16427.
29. Wong SM, Bernui M, Shen H, Akerley BJ (2013) Genome-wide fitness profiling reveals adaptations required by Haemophilus in coinfection with influenza A virus in the murine lung. Proc Natl Acad Sci USA 110:15413–15418.
30. Wong SM, Shaughnessy J, Ram S, Akerley BJ (2016) Defining the binding region in factor H to develop a therapeutic factor H-Fc fusion protein against non-typeable Haemophilus influenzae. Front Cell Infect Microbiol 6:40.
31. Christensen D, Mortensen R, Rosenkrands I, Dietrich J, Andersen P (2017) Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses. Mucosal Immunol 10:260–270.
32. Wang Y, et al. (2017) Cross-protective mucosal immunity mediated by memory Th17 cells against Streptococcus pneumoniae lung infection. Mucosal Immunol 10: 250–259.
33. Wong SM, Akerley BJ (2012) Genome-scale approaches to identify genes essential for Haemophilus influenzae pathogenesis. Front Cell Infect Microbiol 2:23.
34. Zygmunt BM, Rharbaoui F, Groebe L, Guzman CA (2009) Intranasal immunization promotes th17 immune responses. J Immunol 183:6933–6938.
35. LeibundGut-Landmann S, et al. (2007) Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 8:630–638.
36. Liu DF, et al. (2004) The C-terminal fragment of the internal 110-kilodalton passenger domain of the Hap protein of nontypeable Haemophilus influenzae is a potential vaccine candidate. Infect Immun 72:6961–6968.
37. Winter LE, Barenkamp SJ (2006) Antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae are opsonophagocytic for both homologous and heterologous strains. Clin Vaccine Immunol 13:1333–1342.
38. Yang Yp, Thomas WR, Chong P, Loosmore SM, Klein MH (1998) A 20-kilodalton N-terminal fragment of the D15 protein contains a protective epitope(s) against Haemophilus influenzae type a and type b. Infect Immun 66:3349–3354.
39. Loosmore SM, et al. (1998) The Haemophilus influenzae HtrA protein is a protective antigen. Infect Immun 66:899–906.
40. Neary JM, Yi K, Karalus RJ, Murphy TF (2001) Antibodies to loop 6 of the P2 porin protein of nontypeable Haemophilus influenzae are bactericidal against multiple strains. Infect Immun 69:773–778.
41. Novotny LA, Jurcisek JA, Pichichero ME, Bakaletz LO (2000) Epitope mapping of the outer membrane protein P5-homologous fimbrin adhesin of nontypeable Haemophilus influenzae. Infect Immun 68:2119–2128.
42. Hotomi M, et al. (2005) A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization. Vaccine 23:1294–1300.
43. Novotny LA, et al. (2009) Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates. Vaccine 28:279–289.
44. Hirano T, Hou Y, Jiao X, Gu XX (2003) Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from nontypeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx. FEMS Immunol Med Microbiol 35:1–10.
45. Moffitt KL, Malley R, Lu YJ (2012) Identification of protective pneumococcal T(H)17 antigens from the soluble fraction of a killed whole cell vaccine. PLoS One 7: e43445.
46. Moffitt KL, et al. (2011) T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization. Cell Host Microbe 9:158–165.
47. Nielsen H (2017) Predicting secretory proteins with SignalP. Methods Mol Biol 1611: 59–73.
48. Bendtsen JD, Kiemer L, Fausbøll A, Brunak S (2005) Non-classical protein secretion in bacteria. BMC Microbiol 5:58.
49. Goodell EW, Higgins CF (1987) Uptake of cell wall peptides by Salmonella typhimu-rium and Escherichia coli. J Bacteriol 169:3861–3865.
50. Ren D, et al. (July 26, 2017) Serum antibody response to Moraxella catarrhalis proteins in stringently defined otitis prone children. Vaccine, 10.1016/j.vaccine.2017.07.027.
51. Roier S, et al. (2012) Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice. PLoS One 7:e42664.
52. Wu W, et al. (2012) Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 186:420–427.
53. Romero-Steiner S, et al. (2004) Measurement of serum bactericidal activity specific for Haemophilus influenzae type b by using a chromogenic and fluorescent metabolic indicator. Clin Diagn Lab Immunol 11:89–93.